Drug intelligence / Profile preview

Ailamide

Development stage
Phase 4
Lead developer
Senju Pharmaceutical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

**Ailamide** is a Japanese fixed-dose ophthalmic suspension containing brimonidine tartrate 0.1% and brinzolamide 1%. It is marketed for reducing elevated intraocular pressure in glaucoma and ocular hypertension when other glaucoma therapies provide insufficient control. Brimonidine is an alpha-2 adrenergic receptor agonist that reduces aqueous-humor production and promotes uveoscleral outflow, while brinzolamide inhibits carbonic anhydrase II to reduce aqueous-humor secretion. The product was approved in Japan in March 2020 and launched in June 2020 by Senju Pharmaceutical with Otsuka Pharmaceutical as its alliance partner. ([otsuka.co.jp](https://www.otsuka.co.jp/en/company/newsreleases/2020/20200616_1.html))

Brand names
Ailamide
Other names
0.1% brimonidine tartrate + 1% brinzolamide fixed-combination ophthalmic suspensionAILAMIDE Combination Ophthalmic Suspensionアイラミド配合懸濁性点眼液
02

Targets

ADRA2B (α2B)ADRA2C (α2C)CA2 (Carbonic Anhydrase 2)ADRA2A (α2A)

Beyond the preview

Go deeper on Ailamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ailamide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call